The prices of the 25 most expensive brand-named drugs covered by Medicare Part D have nearly doubled, rising by an average of 98% since they entered the market, according to a new analysis by the AARP Public Policy Institute.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
